Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NYSE: CGC) officially revealed its Cannabis 2.0 portfolio of products last week, set to come to market as part of the second wave of Canadian cannabis commercialization. With December 16, 2019, being the first date new product formats can be sold into distribution channels, the…
RISE Life Science Corp. (CSE: RLSC) (the “Company” or “RISE”), a company developing hemp-based products for the emerging CBD consumer category, today announces that it will discontinue its physical retail operations in California, and will focus its efforts on distribution partnerships and online sales of its ‘nano’ hemp-extract oral sprays, quick-dissolve oral tablets and topical…
HEXO Corp. (“HEXO” or the “Company”) (TSX:HEXO; NYSE:HEXO) is pleased to announce the closing of its previously announced private placement of unsecured convertible debentures for aggregate gross proceeds of $70 million (the “Offering”). The Company intends to use the net proceeds of the Offering for working capital and general corporate purposes. “This financing demonstrates that…
2019 has been a tough year for the Canadian cannabis industry and this is a trend that we continue to closely monitor. In the near future, we are going to see new products come to market that fall under the cannabis derivative category and this emerging opportunity is commonly being referred to as Cannabis 2.0.…
WASHINGTON, D.C., (December 5, 2019)—The Global Alliance for Cannabis Commerce (GACC), a trade organization representing a major cross-section of the global cannabis industry, today announced the launch of a nationwide, voluntary industry certification standard for safety and purity in cannabis product testing. It is expected by the end of 2020 this program will be available…
As cannabis legalization spreads, scientists and policymakers are keeping a close eye on the change it brings to healthcare. While legalizing cannabis can affect many aspects of life, one of the most studied is how it influences public health problems in America. Being a medicine first and foremost, it’s natural that cannabis ends up in…
New study suggests CBD maintains homeostasis of primary immune response to dampen out-of-control inflammation. A recent study in the journal Cannabis and Cannabinoid Research (2019), concluded that their data on CBD “overwhelmingly demonstrates” it contains immune suppressive and anti-inflammatory properties. The study showed that CBD regulates primary immune response by directly suppressing target cells, such…
Auxly Cannabis Group Inc. (TSX.V – XLY) (“Auxly” or the “Company”) today announced that it has entered into an agreement with every Canadian province (except Quebec) to commence sales of cannabis 2.0 products (extracts, edibles and topicals) and has secured in excess of 250 listings in the aggregate for its vape, chocolate and chewable products…
During the last year, we have been following a number of high-growth trends that are expected to continue in 2020 and at the same time have been working to identify companies that are levered to such trends. From cannabis to edible mushrooms, we have seen a significant increase in the amount of interest in these…
Isracann Biosciences Inc.  (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer for both domestic and European export sales, is pleased to announce it has received a phase 1 project profile report and has been advised that the project characterization project is fully…